AlphAIAlphAI — Financial news for AI agents
StockNASDAQ · US · USDHealthcare · Biotechnology

$AVLN

Avalyn Pharma Inc.

Price · $AVLNvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $AVLN in the last 7 days.

Insider · 30dAll trades →

No SEC Form 4 filings for $AVLN in the last 30 days.

See all $AVLN insider activity →
Top stories · $AVLNMore →
OCT 2·investing.comMed

Raymond James initiates Avalyn Pharma stock coverage with outperform rating

Raymond James initiated coverage on Avalyn Pharma (NASDAQ:AVLN) with an outperform rating and a $60 price target, implying over 118% upside. The company is developing inhaled antifibrotics for pulmonary fibrosis, with two Phase 2 assets. Avalyn's market cap is $1.22B, and it has a strong balance sheet. Raymond James expects catalysts in late 2027, while InvestingPro suggests the stock may be overvalued.

SEP 16·SEC EDGAR 8-K

Avalyn Pharma Inc. (AVLN): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Avalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Director On September 15, 2026 (the “Effective Date”), upon the recommendation of the Nominating and Corpora

AUG 12·rttnews.com

Avalyn Advances Inhaled Fibrosis Therapies; MIST Phase 2b Enrollment Completed

Avalyn Pharma (AVLN) reported Q2 2026 results and said enrollment is complete for the global Phase 2b MIST trial of inhaled AP01 (pirfenidone) in progressive pulmonary fibrosis. The randomized, double-blind study enrolled 398 patients vs a 375 target, with 52-week safety and efficacy and topline data expected in H2 2027. Q2 R&D was $24.7M, net loss $28.9M, and cash $413.5M.

AVLN sentiment & insider activity

Recent AVLN coverage spans corporate actions, financial news and technology.

What's driving AVLN

  • Analyst upgrade to outperform with a high price target suggests upside potential.

    investing.com · Oct 2, 2026

  • Governance change with modest compensation impact; unlikely to move price materially.

    SEC EDGAR 8-K · Sep 16, 2026

  • Enrollment completion de-risks trial execution and sets expectations for topline MIST data in 2H 2027, supporting a longer-dated catalyst path.

    rttnews.com · Aug 12, 2026

  • The filing adds concrete trial execution progress and extends the cash runway to 2029, supporting a longer-dated risk window for AVLN.

    SEC EDGAR 8-K · Aug 12, 2026

  • This reads more like a listing/positioning catalyst than a new fundamental datapoint, with limited incremental earnings or trial results detail.

    rttnews.com · Aug 10, 2026

AlphAI scores every news story that mentions AVLN with an AI model for sentiment and relevance, and aggregates insider trades from Avalyn Pharma Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $AVLN

Score
OCT 2$AVLNMedinvesting.com

Raymond James initiates Avalyn Pharma stock coverage with outperform rating

Raymond James initiated coverage on Avalyn Pharma (NASDAQ:AVLN) with an outperform rating and a $60 price target, implying over 118% upside. The company is developing inhaled antifibrotics for pulmonary fibrosis, with two Phase 2 assets. Avalyn's market cap is $1.22B, and it has a strong balance sheet. Raymond James expects catalysts in late 2027, while InvestingPro suggests the stock may be overvalued.

2 min read
SEP 16$AVLNLowSEC EDGAR 8-K

Avalyn Pharma Inc. (AVLN): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Avalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Director On September 15, 2026 (the “Effective Date”), upon the recommendation of the Nominating and Corpora

1 min read
AUG 12$AVLNMedrttnews.com

Avalyn Advances Inhaled Fibrosis Therapies; MIST Phase 2b Enrollment Completed

Avalyn Pharma (AVLN) reported Q2 2026 results and said enrollment is complete for the global Phase 2b MIST trial of inhaled AP01 (pirfenidone) in progressive pulmonary fibrosis. The randomized, double-blind study enrolled 398 patients vs a 375 target, with 52-week safety and efficacy and topline data expected in H2 2027. Q2 R&D was $24.7M, net loss $28.9M, and cash $413.5M.

6 min read
AUG 12$AVLNMedSEC EDGAR 8-K

Avalyn Reports Second Quarter 2026 Financial Results and Recent

Avalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Avalyn Reports Second Quarter 2026 Financial Results and Recent Business Highlights Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 Two abstracts accepted for presentation at the European Respiratory S

4 min read
AUG 10$HALOMedrttnews.com

Biotech Stocks At 52-Week Highs - HALO +20% On Q2 Results, FENC, AVLN, AMLX, CHE

Biotech stocks hit 52-week highs Aug. 7, 2026. Halozyme (HALO) rose 20% after Q2 revenue of $481M (+48% Y/Y) and 2026 revenue guidance of $1.83B-$1.91B. Fennec (FENC) reached $11.66 on PEDMARK sales of $15.1M (+71% Y/Y). Avalyn (AVLN) hit $34.15. Amylyx (AMLX) hit $24.60. Chemed (CHE) rose to $552.72 after Q2 revenue $673M (+8.8%) and 2026 growth guidance of 8.25%-9.25%.

7 min read
JUL 1$AVLNLowSEC EDGAR 8-K

Avalyn Pharma Inc. (AVLN): Entry into a Material Definitive Agreement

Avalyn Pharma Inc. (AVLN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 2 ck0001540171-ex10_1.htm EX-10.1 EX-10.1 Exhibit 10.1 FIRST AMENDMENT TO SUBLEASE THIS FIRST AMENDMENT TO SUBLEASE (this “ Amendment ”) is made and entered into as of June 29, 2026 (the “ Effective Date ”), by and between CRISPR THERAPEUTICS, INC., a Delaware corporation

4 min read

Related tickers

More in Biotechnology